pentobarbital will lessen the level or impact of guanfacine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Closely. Powerful or moderate CYP3A4 inducers drastically reduce guanfacine plasma concentrations and elimination fifty percent-everyday living.
pentobarbital raises effects of ifosfamide by affecting hepatic enzyme CYP2B6 metabolism. Use Warning/Check. Coadministration of ifosfamide with CYP2B6 inducers may perhaps raise metabolism of ifosfamide to its metabolite. Observe for greater effects/toxicities if mixed with CYP2B6 inducers.
pentobarbital will lower the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Intently. The efficacy of hormonal contraceptives could be lowered.
pentobarbital will decrease the level or impact of alprazolam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
If inducer is discontinued, look at oliceridine dosage reduction and observe for signs of respiratory depression.
pentobarbital will decrease the extent or result of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
benzhydrocodone/acetaminophen and pentobarbital the two boost sedation. Keep away from or Use Alternate Drug. Limit use to people for whom alternate cure selections are insufficient
Reserve concomitant prescribing of such drugs in sufferers for whom other remedy choices are inadequate. more info Limit dosages and durations on the minimum necessary. Watch carefully for signs of respiratory despair and sedation.
pentobarbital will lower the level or outcome of etonogestrel by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
Aged or debilitated sufferers could respond to barbiturates with marked depression, enjoyment, and confusion; in some sufferers, barbiturates regularly create enjoyment in lieu of despair
Should the buprenorphine dose is insufficient as well as the CYP3A4 inducer cannot be minimized or discontinued, transition the patient again into a buprenorphine formulation that allows dose adjustments.
buprenorphine subdermal implant and pentobarbital each raise sedation. Keep away from or Use Alternate Drug. Limit use to people for whom alternate procedure options are inadequate
Contraindicated (1)pentobarbital will decrease the level or outcome of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is actually a delicate CYP3A4 substrate. Coadministration with powerful or reasonable CYP3A4 inducers is contraindicated.
pentobarbital will lower the extent or influence of vinorelbine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unknown.